Hemispherx Analysis of New Data on Protection From Pulmonary Damage Associated With Infection by Highly Pathogenic Influenza Virus
January 22, 2014 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Jan. 22, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB), today announced that Dr. William M. Mitchell of Vanderbilt University presented a research paper on January 21,...
Hemispherx Presents New Data on Protection From Pulmonary Damage Associated With Infection by Highly Pathogenic Influenza Virus
January 21, 2014 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Jan. 21, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB), today announced that Dr. William M. Mitchell of Vanderbilt University will present a research paper on January 21,...
Hemispherx Biopharma to Present on January 15 at the Biotech Showcase Held in Conjunction With the 32nd JP Morgan Healthcare Conference in San Francisco
January 13, 2014 08:00 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Jan. 13, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB), today announced it will make a presentation at the Biotech Showcase held in conjunction with the 32nd JP Morgan...
Hemispherx Biopharma Reports Evidence Based Clinical Potential of a Natural Interferon (IFN) -- Alpha for Infection Control and Treatment of Drug Resistant H7N9 Influenza Virus
January 07, 2014 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Jan. 7, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") today announced publication of an article entitled "Emergence of a novel drug...